stock options

Inhibikase Therapeutics grants 685,718 stock options at $1.68/share to five new hires under Nasdaq inducement plan with ten-year terms.

Taysha Gene Therapies grants 300,000 RSUs and options to purchase 92,400 shares to four new employees under its 2023 Inducement Plan.

MBX Biosciences grants new Chief Business Officer Karen Basbaum 130,000 stock options worth ~$4.2M as inducement award under Nasdaq regulations.

Kura Oncology granted 153,750 stock options at $8.34/share to six new employees under Nasdaq Rule 5635(c)(4), valued at approximately $1.28 million, with standard four-year vesting.

BFA Law investigates Willis Lease Finance board for fiduciary duty breaches over executive compensation that doubled to $14.2M, raising shareholder governance concerns.

Osisko Development distributed 1.1M stock options and 1.4M restricted share units to executives and employees as part of annual compensation strategy.

Zentalis Pharmaceuticals granted 36,000 stock options at $2.57/share to two new hires under Nasdaq inducement rules, vesting over four years.

Vor Bio awarded stock options and RSUs to nine newly hired employees as employment inducements, with options exercisable at $17.39 per share over a 10-year term.

Sionna CLO liquidated 10,250 shares for $347k via pre-scheduled plan while retaining 50,935 options. Dual clinical trials expected mid-2026 with $310.3M cash runway through 2028.

Damora Therapeutics appoints Jennifer Jarrett as CEO, grants her 2M share awards. Company also awards equity to four new employees under Nasdaq inducement rules.

Liquidia's Chief Commercial Officer sold 80,000 shares worth $2.8M through pre-arranged plan while retaining substantial holdings as flagship product Yutrepia drives record quarterly profits.

Meta targets $9 trillion market cap by 2031 via executive stock options. Despite low probability, $META trades cheaply at 19x forward earnings with strong advertising profits and AI upside.

LeMaitre Vascular stock rises 30% annually after Q4 results showed 16% sales growth and 47% operating income gains, despite a senior executive selling $285K in shares.

Quantum BioPharma grants 35,000 stock options to employees at CA$6.50 strike, vesting immediately with five-year exercise window.

Ligand Pharmaceuticals CFO Octavio Espinoza sold $688K in stock under a prearranged plan. The sale reflects portfolio diversification, not concerns, as the biotech firm posts strong 2025 results.

Meta ties executive compensation to reaching $9 trillion market cap by 2031, requiring 500% growth. Plan reflects AI ambitions despite scale challenges.

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.

Visteon CEO Sachin Lawande sold 49,453 shares worth $4.62M via pre-scheduled trading plan, reducing holdings by 13% while maintaining over 321,000 shares.

Meta launches aggressive stock option program targeting $9 trillion valuation within five years, offering senior executives massive payouts if AI bet succeeds.

Getty Copper appoints Ryan O'Regan as CEO and Dr. Roy Greig as VP Exploration, grants 22.45M stock options, and hires marketing firms to boost investor awareness.